Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) reported substantial financial improvements for the first half of 2025, with revenues increasing to $773,000 compared to $284,000 in the prior-year period. This growth reflects continued expansion in the company's contract development and manufacturing organization (CDMO) business unit, which has booked $1.0 million in service orders through August 2025.
The company's research and development expenses decreased significantly to $1.24 million from $2.79 million in the comparable period, while marketing, general and administrative expenses rose to $1.26 million from $1.00 million. Net loss narrowed to $4.13 million compared to $4.48 million a year earlier, demonstrating improved operational efficiency and cost management.
Scinai's cash position strengthened considerably, with cash and equivalents totaling $989,000 as of June 30, 2025. The company further enhanced its liquidity by raising an additional $4.2 million in July and August under its Standby Equity Purchase Agreement. This financial stability is crucial for advancing the company's pipeline development and supporting ongoing operations.
The company made significant progress in its anti-IL-17 NanoAb program, filing new patents under its collaboration with Max Planck Institute. Scinai is actively pursuing up to €27 million in grant funding to support clinical trials and pipeline development activities. These developments are particularly important given the company's focus on inflammation and immunology biological therapeutic products targeting diseases with large unmet medical needs.
Scinai's dual business model combines in-house development of innovative VHH antibody fragments (nanoAbs) with boutique CDMO services providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design services for early stage biotech projects. The latest financial results and operational updates are available in the company's newsroom at https://ibn.fm/SCNI.
The improved financial performance and strengthened cash position position Scinai to accelerate its therapeutic development programs while maintaining its CDMO growth trajectory. This progress is significant for investors and the broader biopharmaceutical industry, as it demonstrates the viability of Scinai's innovative approach to addressing unmet medical needs through advanced antibody fragment technology and complementary service offerings.
